Glycylcyclines

Glycylcyclines represent a new group of antibiotics that is derived from the tetracycline antibiotic minocycline. The main representative is tigecycline'. Tigecycline is a broad-spectrum ATB (effective against Gram-negative, Gram-positive and anaerobic microbes, but not effective against pseudomonads and proteums). Tigecycline is chemically a ``9-t-butylglycylamido derivative of minocycline.

Indication[edit | edit source]

They are indicated for complicated skin and soft tissue infections as well as intra-abdominal infections.

Mechanism of action[edit | edit source]

Their mechanism of action is: inhibition of proteosynthesis, (blocking of translation of protein in bacteria by binding to the ribosomal subunit 30S', blocks the entry of aminoacyl-tRNA molecules into the A site of the ribosome ).

Antimicrobial spectrum[edit | edit source]

It is a broad-spectrum antibiotic' that acts on many clinically important bacteria. Both gram-positive, gram-negative, anaerobic and atypical, including some multi-resistant, penicillin resistant Streptococcus pneumoniae, Klebsiella pneumoniae and Escherichia coli , Staphylococcus aureus, from gram-negative bacteria shows a lower sensitivity to Pseudomonas aeruginosa, Proteus mirabilis, Burkholderia cepacia and Stenotrophomonas malthophilia.

Side effects[edit | edit source]

Side effects are:

Links[edit | edit source]

References[edit | edit source]

VOJTOVÁ, Vladimíra – URBÁNEK, Karel. Glycylcykliny - Nová skupina antibiotik. Klin Farmakol Farm [online]. -2008, y. 3, p. 113–115, Available from <http://www.solen.cz/pdfs/far/2008/03/06.pdf>. ISSN 1803-5353.